These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 16044777)

  • 1. [An addition concerning spironolactone and eplerenone (Inspra) in heart failure].
    Swedberg K
    Lakartidningen; 2005 Jun 13-26; 102(24-25):1924. PubMed ID: 16044777
    [No Abstract]   [Full Text] [Related]  

  • 2. [Explanation on indications and cost-efficiency of Inspra].
    Ohlsson-Onerud A; Pettersson B
    Lakartidningen; 2005 Jul 11-24; 102(28-29):2087; discussion 290-2. PubMed ID: 16097182
    [No Abstract]   [Full Text] [Related]  

  • 3. [Inspra and the drug benefits board: What is the role of the drug committees?].
    Hoffmann M; Dahlqvist R; Levin LA; Silfverhielm B; Skoglund I; Vinge E
    Lakartidningen; 2005 Jul 11-24; 102(28-29):2088, 2090; discussion 290-2. PubMed ID: 16097183
    [No Abstract]   [Full Text] [Related]  

  • 4. [LFN's evaluation of Inspra illustrates the need of drug committees!].
    Malmström R; Hjemdahl P
    Lakartidningen; 2005 May 30-Jun 5; 102(22):1751-2. PubMed ID: 15987055
    [No Abstract]   [Full Text] [Related]  

  • 5. Eplerenone in the treatment of chronic heart failure.
    Krum H; Liew D
    Expert Rev Cardiovasc Ther; 2004 May; 2(3):315-20. PubMed ID: 15151479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
    Prescrire Int; 2006 Apr; 15(82):46-9. PubMed ID: 16604728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eplerenone (Inspra).
    Med Lett Drugs Ther; 2003 May; 45(1156):39-40. PubMed ID: 12736599
    [No Abstract]   [Full Text] [Related]  

  • 8. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
    Barnes BJ; Howard PA
    Ann Pharmacother; 2005 Jan; 39(1):68-76. PubMed ID: 15590870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug insight: aldosterone-receptor antagonists in heart failure--the journey continues.
    Kalidindi SR; Tang WH; Francis GS
    Nat Clin Pract Cardiovasc Med; 2007 Jul; 4(7):368-78. PubMed ID: 17589427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eplerenone after myocardial infarction?
    Drug Ther Bull; 2008 Jan; 46(1):1-3. PubMed ID: 18171726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of aldosterone receptor antagonists in the management of heart failure: an update.
    Nagarajan V; Chamsi-Pasha M; Tang WH
    Cleve Clin J Med; 2012 Sep; 79(9):631-9. PubMed ID: 22949344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure.
    Weintraub WS; Zhang Z; Mahoney EM; Kolm P; Spertus JA; Caro J; Ishak J; Goldberg R; Tooley J; Willke R; Pitt B
    Circulation; 2005 Mar; 111(9):1106-13. PubMed ID: 15723981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
    Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS
    Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inspra improves survival for CHF patients.
    Wimett L; Laustsen G
    Nurse Pract; 2004 Jul; 29(7):56-9. PubMed ID: 15238861
    [No Abstract]   [Full Text] [Related]  

  • 16. Ethics and eplerenone.
    Gupta S; Fugh-Berman AJ; Scialli A
    J Med Ethics; 2013 Feb; 39(2):110-4. PubMed ID: 23015747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study].
    Watanabe J
    Nihon Rinsho; 2007 Apr; 65 Suppl 4():543-6. PubMed ID: 17508588
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study.
    Krum H; Shi H; Pitt B; McMurray J; Swedberg K; van Veldhuisen DJ; Vincent J; Pocock S; Zannad F;
    Circ Heart Fail; 2013 Jul; 6(4):711-8. PubMed ID: 23625945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Eplerenone Post-AMI Heart Failure Efficacy and survival study (EPHESUS)].
    Takata Y; Asano K; Yamashina A
    Nihon Rinsho; 2005 Mar; 63 Suppl 3():336-41. PubMed ID: 15813091
    [No Abstract]   [Full Text] [Related]  

  • 20. [Therapy of heart failure after myocardial infarction. With eplerenone a new course].
    MMW Fortschr Med; 2004 Oct; 146(43):58-9. PubMed ID: 15559524
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.